**Analysis:**
- **Performance vs. Expectations:** Merck reported strong Q4 and full-year 2007 results, with revenue growth and non-GAAP EPS beating expectations.
- **Management's Tone:** CEO Richard Clark and CFO Peter Kellogg expressed confidence in the company's future, despite short-term challenges.
- **Guidance Updates:** The company reaffirmed its 2008 non-GAAP EPS guidance but lowered its GAAP EPS guidance due to restructuring costs and other factors.
- **External/Macro Influences:** The stock market and economic outlook were mentioned as challenges, but the company's focus on innovation and execution was seen as mitigating factors.

**Conclusion:**
The short-term impact on the stock price is likely to be positive, driven by the strong performance and reaffirmed guidance. However, the stock may face some volatility due to ongoing regulatory uncertainty and market hype around the ENHANCE trial. Overall, the company's focus on innovation and execution suggests long-term potential, but the stock may experience short-term fluctuations.

**Rating:**
1